Table 2 Endpoints during follow-up among stage 1 serological suspects who attended at least one control visit, by site
From: Estimates of the duration of the early and late stage of gambiense sleeping sickness
Adjumani, Uganda | Arua, Uganda | Moyo, Uganda | Yumbe, Uganda | Kiri, s. Sudan | Maridi, s. Sudan | Total | |
|---|---|---|---|---|---|---|---|
Not included in survival analysis | |||||||
Dead (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 0 (0.0) | 1 (0.03) |
Non-case (CATT reactivity waned) (%) | 279 (58.1) | 1198 (66.4) | 13 (27.7) | 21 (61.8) | 326 (46.6) | 51 (45.1) | 1888 (59.4) |
Persistent suspect (%) | 102 (21.3) | 491 (27.2) | 10 (21.3) | 11 (32.4) | 330 (47.2) | 47 (41.6) | 991 (31.2) |
Included in survival analysis | |||||||
Confirmed stage 1 HAT (%) | 61 (12.7) | 87 (4.8) | 18 (38.3) | 1 (2.9) | 23 (3.3) | 9 (8.0) | 199 (6.3) |
Progressed to stage 2 HAT (%) | 38 (7.9) | 29 (1.6) | 6 (12.8) | 1 (2.9) | 19 (2.7) | 6 (5.3) | 99 (3.1) |
Total | 480 | 1805 | 47 | 34 | 699 | 113 | 3178 |
Median number of days between detection as stage 1 serological suspect and stage 2 diagnosis (IQR) | 179 (99–319) | 206 (181–409) | 213 (103–417) | 198 (single observation) | 135 (109–221) | 64 (28–168) | 189 (104–319) |